JP3642945B2 - Skin pretreatment agent - Google Patents
Skin pretreatment agent Download PDFInfo
- Publication number
- JP3642945B2 JP3642945B2 JP07218498A JP7218498A JP3642945B2 JP 3642945 B2 JP3642945 B2 JP 3642945B2 JP 07218498 A JP07218498 A JP 07218498A JP 7218498 A JP7218498 A JP 7218498A JP 3642945 B2 JP3642945 B2 JP 3642945B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- pretreatment agent
- skin pretreatment
- lotion
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Cosmetics (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は皮膚プレトリートメント剤に関する。更に詳しくは、化粧水の使用の前に皮膚に塗布することにより、化粧水が含有する低分子水溶性有効成分の経皮吸収性を高め、化粧水の効果を高める皮膚プレトリートメント剤に関する。
【0002】
【従来の技術】
皮膚に対し有効性を示す物質には、荒れ肌改善物質であるジイソプロピルアミンジクロロアセテートやコラーゲン産生促進物質であるアスコルビン酸誘導体などの水溶性物質が多い。そこで水溶性物質を含有した化粧水剤形の皮膚外用剤が多く提案されている。一方、一般に水溶性物質は油溶性物質に比較して経皮吸収性が低い。そこで、水溶性物質の経皮吸収性を高める物質の探索が行われている。これまでにもセスキテルペン類やイソステアリン酸などの油剤に水溶性物質の経皮吸収促進効果を見出した(特開平6−135821号公報など)。これら経皮吸収促進物質は吸収促進させたい水溶性物質と同一製剤中に共存することによりその効果を示す。しかしながら、上記油剤を共存させた場合、製剤は乳化物となり、安定性や感触など剤形上の制約を受ける。よって、官能的に好まれ、熱力学的に安定な化粧水剤中に配合された水溶性成分を効率よく皮膚から吸収させることは困難であった。
【0003】
【発明が解決しようとする課題】
本発明は、このような実情に鑑みなされたものであって、化粧水が含有する低分子水溶性有効成分の経皮吸収性を高める皮膚プレトリートメント剤を提供することを目的とするものである。
【0004】
【課題を解決するための手段】
上記の目的を達成するために、本発明の皮膚プレトリートメント剤は、経皮吸収促進効果を有する極性油剤を配合することを特徴とするものである。
【0005】
【発明の実施の形態】
以下、本発明の実施の形態を述べる。一般に経皮吸収促進物質は吸収促進させたい水溶性物質と同一製剤中に共存する。本発明の皮膚プレトリートメント剤は化粧水の使用の前に皮膚に塗布することにより、化粧水が含有する低分子水溶性有効成分の経皮吸収性を高め、有効成分の効果を高める。
【0006】
本発明の皮膚プレトリートメント剤に用いられる極性油剤としては、例えばイソステアリン酸、オレイン酸、イソ型長鎖脂肪酸、アンテイソ型長鎖脂肪酸などの高級脂肪酸、オリーブ油、マカデミアナッツ油などの植物油、リモネン、水素添加ビサボロール等のテルペン類、2−エチルヘキサン酸グリセリルなどのトリグリセリド、ミリスチン酸イソプロピル等のエステル油が挙げられる。極性油剤の配合量は、プレトリートメント剤(組成物)の総量を基準として各々0.01〜10重量%(以下、wt%と略記する)が望ましい。これらの配合量の上限を超えても、その越えた配合量に見合った効果は期待できず、また下限未満の配合量では本発明の目的を達成することができない場合がある。
【0007】
本発明の皮膚プレトリートメント剤は医薬品、化粧品等に適用でき、剤形としては例えば、乳液類、クリーム類、パック類、マッサージ料類等に適用することができる。本発明の皮膚プレトリートメント剤のpHは6〜8が望ましい。6未満であると塩基性物質の吸収が悪く、8を超えると酸性物質の吸収が悪くなる場合がある。
【0008】
尚、本発明の皮膚プレトリートメント剤には上記の他にタール系色素、酸化鉄などの着色顔料、パラベン、フェノキシエタノールなどの防腐剤、ジメチルポリシロキサン、メチルフェニルポリシロキサン等のシリコン油、パラフィン、ワセリン等の炭化水素類、ミツロウ、モクロウ、カルナバロウ等のロウ類、エタノール等の低級アルコール類、セタノール、ベヘニルアルコール、ステアリルアルコール等の高級アルコール類、コレステロール、フィトステロール、分岐脂肪酸コレステロールエステル等のステロール類、硬化油等の加工油類、セチル硫酸ナトリウム、N−ステアロイル−L−グルタミン酸塩、グリチルリチン酸塩などの陰イオン界面活性剤、ポリオキシエチレンアルキルエーテル、ポリオキシエチレン脂肪酸エステル、ポリオキシエチレン多価アルコール脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油、多価アルコール脂肪酸エステル、ポリグリセリン脂肪酸エステル、変性シリコン、蔗糖エステルなどの非イオン界面活性剤、テトラアルキルアンモニウム塩などの陽イオン界面活性剤、ベタイン型、スルホベタイン型、スルホアミノ酸型などの両性界面活性剤、レシチン、リゾフォスファチジルコリン、セラミド、セレブロシドなどの天然系界面活性剤、酸化チタン、酸化亜鉛などの顔料、ジブチルヒドロキシトルエンなどの抗酸化剤、塩化ナトリウム、塩化マグネシウム、硫酸ナトリウム、硝酸カリウム等の無機塩類、クエン酸ナトリウム、酢酸カリウム、琥珀酸ナトリウム、アスパラギン酸ナトリウム等の有機酸塩類、塩酸エタノールアミン、硝酸アンモニウム、塩酸アルギニン等の塩類、エデト酸等のキレート剤、キサンタンガム、カルボキシビニルポリマー、カラギーナンアルキル変性カルボキシビニルポリマー等の増粘剤、水酸化カリウム、ジイソプロパノールアミン、トリエタノールアミン等の中和剤、ヒアルロン酸、コラーゲン等の生体高分子、乳酸菌、酵母などの培養生成物、カミツレ、アロエ、モモ、カロット、スギナ、クワ、桃の葉、セージ、ビワ葉、キュウカンバー、セイヨウキズタ、ハイビスカス、ウコン、ローズマリー、甘草等の植物エキス、セリン、スレオニン等のアミノ酸、ヒドロキシメトキシベンゾフェノンスルフォン酸塩等の紫外線吸収剤、ジプロピレングリコール、1,3ブチレングリコール、グリセリン、プロピレングリコール、ソルビトール、マルビトール、ジグリセリンなどの多価アルコール等が挙げられるがこれに限定されるものではない。
【0009】
【実施例】
以下、実施例及び比較例に基づいて本発明を詳細に説明する。尚、実施例に記載の経皮吸収量測定試験、荒れ肌改善試験は下記の通りである。
【0010】
(経皮吸収量測定試験)
フランツ型垂直セルにヘアレスラットの腹部皮膚を装着し、表1に示す実施例1の本発明の皮膚プレトリートメント剤(pH6.8)を塗布した後、14Cでラベルしたジイソプロピルアミン200000dpmを含む化粧水を1ml乗せた後、24時間後の透過量を液体シンチレーションカウンターにて測定した。対照(比較例1)として本発明のプレトリートメント剤を塗布せずに14Cでラベルしたジイソプロピルアミンを含む化粧水を1ml乗せた後、同様にして測定した。
【0011】
(荒れ肌改善試験)
成人女性30名の顔面に表1に示す実施例1の本発明の皮膚プレトリートメント剤(pH6.8)を塗布した後、化粧水(ジイソプロピルアミンジクロロアセテート0.5%、エタノール5%、グリセリン3%、ジプロピレングリコール10%、精製水残量)を塗布した(一日2回)。対照(比較例1)として、本発明のプレトリートメント剤を塗布せずに上記と同様のジイソプロピルアミンジクロロアセテート0.5%配合化粧水のみを塗布した(一日2回)。荒れ肌改善の効果は、3週間後の荒れ肌の改善の見られた人数で示した。
(1)組成
【0012】
【表1】
【0013】
(2)特性
各試験例の前記諸特性を試験した結果を表2に示す。この表に示す如く、本発明の皮膚プレトリートメント剤(実施例1)は皮膚プレトリートメント剤を用いない比較例1に比べ、優れた経皮吸収促進性、荒れ肌改善効果を示した。
【0014】
【表2】
【0015】
【発明の効果】
以上記載のごとく、本発明が、化粧水が含有する低分子水溶性有効成分の経皮吸収性を高める皮膚プレトリートメント剤を提供することは明らかである。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a skin pretreatment agent. More specifically, by applying to the skin prior to use lotion, enhance transdermal absorption of the low molecular water soluble active ingredient lotion contains, related skin pretreatment agent to enhance the effect of the lotion.
[0002]
[Prior art]
Substances that are effective against the skin include many water-soluble substances such as diisopropylamine dichloroacetate, which is a rough skin improving substance, and ascorbic acid derivatives, which are collagen production promoting substances. Thus, many skin external preparations containing a water-soluble substance have been proposed. On the other hand, water-soluble substances are generally less transdermally absorbable than oil-soluble substances. Therefore, a search for a substance that enhances the transdermal absorbability of a water-soluble substance has been conducted. So far, an oil agent such as sesquiterpenes and isostearic acid has been found to promote transdermal absorption of a water-soluble substance (Japanese Patent Laid-Open No. 6-135821). These percutaneous absorption-enhancing substances exhibit their effects when they coexist in the same preparation with a water-soluble substance to be absorbed. However, when the above oil agent coexists, the preparation becomes an emulsion and is restricted in dosage form such as stability and feel. Therefore, it has been difficult to efficiently absorb the water-soluble component blended in the cosmetically preferred and thermodynamically stable lotion from the skin.
[0003]
[Problems to be solved by the invention]
The present invention was made in view of such circumstances, it is an object to provide a skin pretreatment agent to enhance the percutaneous absorbability of the low-molecular water-soluble active ingredient lotion contains .
[0004]
[Means for Solving the Problems]
In order to achieve the above object, the skin pretreatment agent of the present invention is characterized by blending a polar oil agent having a transdermal absorption promoting effect.
[0005]
DETAILED DESCRIPTION OF THE INVENTION
Embodiments of the present invention will be described below. In general, a transdermal absorption enhancer coexists in the same preparation with a water-soluble substance to be absorbed. When the skin pretreatment agent of the present invention is applied to the skin before the use of the skin lotion, the percutaneous absorbability of the low molecular weight water-soluble active ingredient contained in the skin lotion is enhanced and the effect of the active ingredient is enhanced.
[0006]
Examples of the polar oil used in the skin pretreatment agent of the present invention include higher fatty acids such as isostearic acid, oleic acid, iso-type long chain fatty acid, anteiso-type long chain fatty acid, vegetable oils such as olive oil and macadamia nut oil, limonene, and hydrogenated Examples include terpenes such as bisabolol, triglycerides such as glyceryl 2-ethylhexanoate, and ester oils such as isopropyl myristate. The blending amount of the polar oil agent is preferably 0.01 to 10% by weight (hereinafter abbreviated as wt%) based on the total amount of the pretreatment agent (composition). Even if the upper limit of these blending amounts is exceeded, an effect commensurate with the exceeding blending amount cannot be expected, and if the blending amount is less than the lower limit, the object of the present invention may not be achieved.
[0007]
The skin pretreatment agent of the present invention can be applied to pharmaceuticals, cosmetics and the like, and the dosage form can be applied to, for example, emulsions, creams, packs, massage materials and the like. The pH of the skin pretreatment agent of the present invention is preferably 6-8. If it is less than 6, absorption of the basic substance may be poor, and if it exceeds 8, absorption of the acidic substance may be deteriorated.
[0008]
In addition to the above, the skin pretreatment agent of the present invention includes tar pigments, colored pigments such as iron oxide, preservatives such as parabens and phenoxyethanol, silicone oils such as dimethylpolysiloxane and methylphenylpolysiloxane, paraffin, and petroleum jelly. Hydrocarbons such as beeswax, beeswax, carnauba wax and the like, lower alcohols such as ethanol, higher alcohols such as cetanol, behenyl alcohol and stearyl alcohol, sterols such as cholesterol, phytosterol and branched fatty acid cholesterol ester, and hardened oil Processing oils such as sodium cetyl sulfate, N-stearoyl-L-glutamate, glycyrrhizinate and the like, polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, poly Nonionic surfactants such as xylethylene polyhydric alcohol fatty acid ester, polyoxyethylene hydrogenated castor oil, polyhydric alcohol fatty acid ester, polyglycerin fatty acid ester, modified silicon, sucrose ester, cationic surfactant such as tetraalkylammonium salt, Amphoteric surfactants such as betaine type, sulfobetaine type, sulfoamino acid type, natural surfactants such as lecithin, lysophosphatidylcholine, ceramide, cerebroside, pigments such as titanium oxide and zinc oxide, dibutylhydroxytoluene, etc. Antioxidants, inorganic salts such as sodium chloride, magnesium chloride, sodium sulfate, potassium nitrate, organic acid salts such as sodium citrate, potassium acetate, sodium oxalate, sodium aspartate, ethanolamine hydrochloride, ammonium nitrate Salts such as nium, arginine hydrochloride, chelating agents such as edetic acid, thickeners such as xanthan gum, carboxyvinyl polymer, carrageenan alkyl-modified carboxyvinyl polymer, neutralizing agents such as potassium hydroxide, diisopropanolamine, triethanolamine, Biopolymers such as hyaluronic acid, collagen, culture products such as lactic acid bacteria, yeast, chamomile, aloe, peach, carrot, horsetail, mulberry, peach leaf, sage, loquat leaf, cucumber, lizard, hibiscus, turmeric, Plant extracts such as rosemary and licorice, amino acids such as serine and threonine, UV absorbers such as hydroxymethoxybenzophenone sulfonate, dipropylene glycol, 1,3 butylene glycol, glycerin, propylene glycol, sorbitol, malbito And polyhydric alcohols such as diglycerin and the like, but are not limited thereto.
[0009]
【Example】
Hereinafter, the present invention will be described in detail based on examples and comparative examples. In addition, the percutaneous absorption measurement test and the rough skin improvement test described in the Examples are as follows.
[0010]
(Transdermal absorption measurement test)
A hairless rat abdomen skin was attached to a Franz-type vertical cell, and after applying the skin pretreatment agent (pH 6.8) of the present invention of Example 1 shown in Table 1, a skin lotion containing 200,000 dpm of diisopropylamine labeled with 14C. After 1 ml was placed, the permeation amount after 24 hours was measured with a liquid scintillation counter. As a control (Comparative Example 1), 1 ml of a lotion containing diisopropylamine labeled with 14C was applied without applying the pretreatment agent of the present invention, and the measurement was performed in the same manner.
[0011]
(Rough skin improvement test)
After applying the skin pretreatment agent (pH 6.8) of the present invention of Example 1 shown in Table 1 on the face of 30 adult women, lotion (diisopropylamine dichloroacetate 0.5%, ethanol 5%, glycerin 3) %, Dipropylene glycol 10%, remaining amount of purified water) were applied (twice a day). As a control (Comparative Example 1), only a lotion containing 0.5% diisopropylamine dichloroacetate similar to the above was applied without applying the pretreatment agent of the present invention (twice a day). The effect of improving rough skin was shown by the number of people who showed improvement of rough skin after 3 weeks.
(1) Composition [0012]
[Table 1]
[0013]
(2) Characteristics Table 2 shows the results of testing the various characteristics of each test example. As shown in this table, the skin pretreatment agent (Example 1) of the present invention exhibited superior transdermal absorption promotion and rough skin improvement effect as compared with Comparative Example 1 in which no skin pretreatment agent was used.
[0014]
[Table 2]
[0015]
【The invention's effect】
As described above, the present invention, it is clear that providing a skin pretreatment agent to enhance the percutaneous absorbability of the low-molecular water-soluble active ingredient lotion contains.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP07218498A JP3642945B2 (en) | 1998-03-20 | 1998-03-20 | Skin pretreatment agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP07218498A JP3642945B2 (en) | 1998-03-20 | 1998-03-20 | Skin pretreatment agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11269033A JPH11269033A (en) | 1999-10-05 |
JP3642945B2 true JP3642945B2 (en) | 2005-04-27 |
Family
ID=13481887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP07218498A Expired - Fee Related JP3642945B2 (en) | 1998-03-20 | 1998-03-20 | Skin pretreatment agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3642945B2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004078185A1 (en) * | 2003-03-04 | 2004-09-16 | Neochemir Inc. | Method of transdermal and transmucosal absorption of carbon dioxide and cosmetic method and therapeutic method |
CZ201110A3 (en) * | 2008-07-10 | 2011-02-09 | Unilever N.V. | Method of lightening skin |
JP5726489B2 (en) * | 2010-11-26 | 2015-06-03 | 株式会社ノエビア | Skin pretreatment agent |
JP5973256B2 (en) * | 2011-06-29 | 2016-08-23 | 株式会社コーセー | Skin care method and cosmetics used therefor |
JP6730241B2 (en) * | 2017-10-04 | 2020-07-29 | 花王株式会社 | Skin care methods |
-
1998
- 1998-03-20 JP JP07218498A patent/JP3642945B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH11269033A (en) | 1999-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100859677B1 (en) | Pharmaceutical compositions for reducing the appearance of dark circles under the eyes | |
BR112020019875A2 (en) | TOPICAL COMPOSITIONS FOR PAIN RELIEF | |
JPS63185912A (en) | Cosmetic | |
JP2021042241A (en) | Composition for external use | |
JP4518367B2 (en) | Pore reducing agent | |
JP3642945B2 (en) | Skin pretreatment agent | |
KR20150072797A (en) | Composition comprising high concentration caffeines | |
JP2001233754A (en) | Emulsion type skin care preparation | |
US9987322B1 (en) | Treatment of pain in peripheral neuropathy using topical hamelia patens extract | |
JPH11139951A (en) | Cosmetic | |
JP7313111B2 (en) | Sebum secretion stimulator and composition for external use | |
JP3441387B2 (en) | Moisturizer, skin cosmetics and bath additives | |
JP6654369B2 (en) | Elastase inhibitor | |
JPH07215838A (en) | Skin external agent | |
JP3556479B2 (en) | Skin pre-treatment agent | |
JPH05301812A (en) | Skin external preparation | |
JPH09176030A (en) | Medicine for stimulating secretion of sebum | |
JPH1160462A (en) | Skin cosmetic | |
JP2001278768A (en) | Skin care preparation | |
JP4647733B2 (en) | Transdermal absorption-enhancing topical agent | |
JP3400313B2 (en) | Percutaneous absorption promoting skin external preparation | |
JP7253328B2 (en) | External pharmaceutical composition | |
JP2007008911A (en) | Cosmetic | |
JP2001206834A (en) | Skin preparation for external use | |
JPH1160433A (en) | Skin cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040805 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040806 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041109 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041125 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20041125 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050125 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050126 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080204 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090204 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090204 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100204 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100204 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110204 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120204 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120204 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130204 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140204 Year of fee payment: 9 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |